Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Qinlock on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Qinlock (ripretinib) is a kinase inhibitor approved by the FDA for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Qinlock is a switch-control kinase inhibitor that blocks KIT and PDGFRA signaling, including many of the resistance mutations that develop after prior treatment with other kinase inhibitors, helping control tumor growth in later lines of GIST therapy.
Qinlock is intended for patients with advanced GIST whose disease has progressed despite treatment with at least three prior kinase inhibitor therapies, including imatinib.
The recommended dose of Qinlock is 150 mg taken orally once daily, with or without food, continued until disease progression or unacceptable toxicity.
Qinlock does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome) has been reported and may require dose modification or temporary withholding of treatment.
New primary skin cancers, including squamous cell carcinoma and melanoma, have occurred. Regular dermatologic examinations are recommended before and during treatment.
Qinlock should not be started in patients with uncontrolled hypertension. Blood pressure should be monitored and managed during treatment.
Cardiac function, including ejection fraction, should be assessed before and periodically during treatment. Qinlock should be permanently discontinued for Grade 3-4 cardiac dysfunction.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Qinlock is manufactured and marketed by Deciphera Pharmaceuticals. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating oncologist confirming GIST diagnosis and prior kinase inhibitor treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for advanced GIST, Qinlock is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Qinlock directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Qinlock should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Qinlock through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Qinlock access.
Delhi's major hospitals assist patients with prescription support and documentation for Qinlock.
Bangalore's specialist network offers access coordination for eligible GIST patients seeking Qinlock.
Chennai-based oncology specialists coordinate Qinlock access alongside comprehensive GIST care.
Hyderabad's care institutions support patients pursuing Qinlock therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Qinlock.
Pune-based specialists assist with prescription support and Qinlock treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Qinlock.
Kochi's specialist units assist patients with the documentation needed for Qinlock access.
Chandigarh's care centers support Qinlock treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Qinlock access process.
Lucknow-based centers assist patients pursuing Qinlock therapy.
Bhubaneswar's institutions support access to Qinlock for eligible patients.
Guwahati's specialists help coordinate Qinlock access for patients across the Northeast.
Patients in other cities across India can also access Qinlock through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
